Published in PLoS One on January 18, 2012
DACT1, an antagonist to Wnt/β-catenin signaling, suppresses tumor cell growth and is frequently silenced in breast cancer. Breast Cancer Res (2013) 1.10
Deubiquitylating enzymes and DNA damage response pathways. Cell Biochem Biophys (2013) 1.03
Unique DNA methylation loci distinguish anatomic site and HPV status in head and neck squamous cell carcinoma. Clin Cancer Res (2013) 1.02
Deubiquitinases and the new therapeutic opportunities offered to cancer. Endocr Relat Cancer (2015) 1.02
Epigenetic silencing of the WNT antagonist Dickkopf 3 disrupts normal Wnt/β-catenin signalling and apoptosis regulation in breast cancer cells. J Cell Mol Med (2013) 1.00
Ubiquitin C-terminal hydrolase l1 in tumorigenesis. Biochem Res Int (2012) 0.93
UCHL1 Is a Putative Tumor Suppressor in Ovarian Cancer Cells and Contributes to Cisplatin Resistance. J Cancer (2013) 0.87
Identification of candidate circulating cisplatin-resistant biomarkers from epithelial ovarian carcinoma cell secretomes. Br J Cancer (2013) 0.86
Regulation of Mutant p53 Protein Expression. Front Oncol (2015) 0.84
Zinc-finger protein 545 inhibits cell proliferation as a tumor suppressor through inducing apoptosis and is disrupted by promoter methylation in breast cancer. PLoS One (2014) 0.80
Anticancer Effect of a Novel Proteasome Inhibitor, YSY01A, via G2/M Arrest in PC-3M Cells in vitro and in vivo. J Cancer (2015) 0.80
DNA methylation is involved in the aberrant expression of miR-133b in colorectal cancer cells. Oncol Lett (2015) 0.79
Regulation of the DNA damage response by ubiquitin conjugation. Front Genet (2015) 0.78
Mus81 knockdown improves chemosensitivity of hepatocellular carcinoma cells by inducing S-phase arrest and promoting apoptosis through CHK1 pathway. Cancer Med (2015) 0.77
Silencing of UCHL1 by CpG promoter hyper-methylation is associated with metastatic gastroenteropancreatic well-differentiated neuroendocrine (carcinoid) tumors. Ann Surg Oncol (2014) 0.77
Protocadherin 17 functions as a tumor suppressor suppressing Wnt/β-catenin signaling and cell metastasis and is frequently methylated in breast cancer. Oncotarget (2016) 0.77
Phosphoproteomic profiling of selenate-treated Alzheimer's disease model cells. PLoS One (2014) 0.76
Ubiquitin carboxy-terminal hydrolase L1 may be involved in the development of mammary phyllodes tumors. Virchows Arch (2013) 0.76
The importance of regulatory ubiquitination in cancer and metastasis. Cell Cycle (2017) 0.75
DACT2 silencing by promoter CpG methylation disrupts its regulation of epithelial-to-mesenchymal transition and cytoskeleton reorganization in breast cancer cells. Oncotarget (2016) 0.75
Knockdown of ubiquitin-specific peptidase 39 inhibited the growth of osteosarcoma cells and induced apoptosis in vitro. Biol Res (2017) 0.75
Exclusive Association of p53 Mutation with Super-High Methylation of Tumor Suppressor Genes in the p53 Pathway in a Unique Gastric Cancer Phenotype. PLoS One (2015) 0.75
Epigenetics of gastroenteropancreatic neuroendocrine tumors: A clinicopathologic perspective. World J Gastrointest Oncol (2017) 0.75
UCHL1 promotes invasion of breast cancer cells through activating Akt signaling pathway. J Cell Biochem (2017) 0.75
The fundamental role of epigenetic events in cancer. Nat Rev Genet (2002) 30.05
Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med (2003) 18.04
Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci U S A (1992) 3.27
The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell (2002) 3.21
USP10 regulates p53 localization and stability by deubiquitinating p53. Cell (2010) 3.17
The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol (2005) 2.86
Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. Hum Mol Genet (2003) 2.24
Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene (2006) 1.82
A simple and fast densitometric method for the analysis of tyrosine hydroxylase immunoreactivity in the substantia nigra pars compacta and in the ventral tegmental area. Brain Res Brain Res Protoc (2005) 1.59
OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation. PLoS One (2008) 1.47
The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer. Breast Cancer Res (2002) 1.42
PGP9.5 promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma. Cancer Res (2005) 1.34
Defective de novo methylation of viral and cellular DNA sequences in ICF syndrome cells. Hum Mol Genet (2002) 1.32
DNA methylation based biomarkers in non-invasive cancer screening. Curr Mol Med (2010) 1.32
Methylation status of the Epstein-Barr virus major latent promoter C in iatrogenic B cell lymphoproliferative disease. Application of PCR-based analysis. Am J Pathol (1999) 1.31
Aberrant promoter methylation of multiple genes during pathogenesis of bladder cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.30
CMTM3, located at the critical tumor suppressor locus 16q22.1, is silenced by CpG methylation in carcinomas and inhibits tumor cell growth through inducing apoptosis. Cancer Res (2009) 1.27
KRAB zinc finger protein ZNF382 is a proapoptotic tumor suppressor that represses multiple oncogenes and is commonly silenced in multiple carcinomas. Cancer Res (2010) 1.26
Epigenetic identification of ubiquitin carboxyl-terminal hydrolase L1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors. Hepatology (2008) 1.25
Reversible monoubiquitination regulates the Parkinson disease-associated ubiquitin hydrolase UCH-L1. J Biol Chem (2007) 1.24
Cytoplasmic sequestration and functional repression of p53 in the mammary epithelium is reversed by hormonal treatment. Cancer Res (2000) 1.22
Promoter methylation and the detection of breast cancer. Cancer Causes Control (2009) 1.18
Silencing of the UCHL1 gene in human colorectal and ovarian cancers. Int J Cancer (2006) 1.15
The tumor suppressor UCHL1 forms a complex with p53/MDM2/ARF to promote p53 signaling and is frequently silenced in nasopharyngeal carcinoma. Clin Cancer Res (2010) 1.13
A survey of methylated candidate tumor suppressor genes in nasopharyngeal carcinoma. Int J Cancer (2011) 1.08
Genomic screening for genes upregulated by demethylation revealed novel targets of epigenetic silencing in breast cancer. Breast Cancer Res Treat (2009) 1.07
DNA methylation and cancer diagnosis: new methods and applications. Expert Rev Mol Diagn (2009) 1.01
High expression of ubiquitin carboxy-terminal hydrolase-L1 and -L3 mRNA predicts early recurrence in patients with invasive breast cancer. Cancer Sci (2006) 0.99
Over-expression of ubiquitin carboxy terminal hydrolase-L1 induces apoptosis in breast cancer cells. Int J Oncol (2008) 0.95
Phospholipase C delta 1 is a novel 3p22.3 tumor suppressor involved in cytoskeleton organization, with its epigenetic silencing correlated with high-stage gastric cancer. Oncogene (2009) 0.93
PLCD1 is a functional tumor suppressor inducing G(2)/M arrest and frequently methylated in breast cancer. Cancer Biol Ther (2010) 0.92
PGP9.5 methylation as a marker for metastatic colorectal cancer. Anticancer Res (2008) 0.91
Epigenetic control of the ubiquitin carboxyl terminal hydrolase 1 in renal cell carcinoma. J Transl Med (2009) 0.91
Epigenetic Signatures in Breast Cancer: Clinical Perspective. Breast Care (Basel) (2010) 0.86
Ubiquitylation and cancer development. Curr Cancer Drug Targets (2008) 0.79
The gene for human neurone specific ubiquitin C-terminal hydrolase (UCHL1, PGP9.5) maps to chromosome 4p14. Ann Hum Genet (1991) 0.78
Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res (2006) 8.08
Divergent signals and cytoskeletal assemblies regulate self-organizing polarity in neutrophils. Cell (2003) 6.46
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood (2002) 4.56
The stress-responsive gene GADD45G is a functional tumor suppressor, with its response to environmental stresses frequently disrupted epigenetically in multiple tumors. Clin Cancer Res (2005) 2.79
Analysis of PALB2/FANCN-associated breast cancer families. Proc Natl Acad Sci U S A (2007) 2.41
Teratoma formation by human embryonic stem cells: evaluation of essential parameters for future safety studies. Stem Cell Res (2009) 2.10
Determinants of ABH expression on human blood platelets. Blood (2004) 2.05
The GTP binding proteins Gem and Rad are negative regulators of the Rho-Rho kinase pathway. J Cell Biol (2002) 1.86
A comprehensive statistical analysis of predicting in vivo hazard using high-throughput in vitro screening. Toxicol Sci (2012) 1.81
Epigenetic disruption of the WNT/beta-catenin signaling pathway in human cancers. Epigenetics (2009) 1.68
WNT5A exhibits tumor-suppressive activity through antagonizing the Wnt/beta-catenin signaling, and is frequently methylated in colorectal cancer. Clin Cancer Res (2008) 1.67
Zinc-finger protein 545 is a novel tumour suppressor that acts by inhibiting ribosomal RNA transcription in gastric cancer. Gut (2012) 1.67
Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology (2008) 1.66
DNA methyltransferase 3B (DNMT3B) mutations in ICF syndrome lead to altered epigenetic modifications and aberrant expression of genes regulating development, neurogenesis and immune function. Hum Mol Genet (2007) 1.65
Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors. J Clin Oncol (2004) 1.65
Activation of the RalGEF/Ral pathway promotes prostate cancer metastasis to bone. Mol Cell Biol (2007) 1.65
Swedish mutant APP suppresses osteoblast differentiation and causes osteoporotic deficit, which are ameliorated by N-acetyl-L-cysteine. J Bone Miner Res (2013) 1.52
SOX4 induces epithelial-mesenchymal transition and contributes to breast cancer progression. Cancer Res (2012) 1.50
Phase I study of prolonged infusion Bryostatin-1 in patients with advanced malignancies. Cancer Biol Ther (2002) 1.50
Mechanisms of cancer metastasis to the bone. Cell Res (2005) 1.49
Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age. AIDS (2015) 1.49
Pharmacokinetics and pharmacodynamics of six epoetin alfa dosing regimens in anemic critically ill patients without acute blood loss. Crit Care Med (2009) 1.48
OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation. PLoS One (2008) 1.47
Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. Carcinogenesis (2006) 1.47
Dual regulation of macrophage migration inhibitory factor (MIF) expression in hypoxia by CREB and HIF-1. Biochem Biophys Res Commun (2006) 1.47
Epigenetic silencing of a Ca(2+)-regulated Ras GTPase-activating protein RASAL defines a new mechanism of Ras activation in human cancers. Proc Natl Acad Sci U S A (2007) 1.43
Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy. Stem Cells (2009) 1.40
The RhoA-binding protein, rhophilin-2, regulates actin cytoskeleton organization. J Biol Chem (2002) 1.36
Critical and reciprocal regulation of KLF4 and SLUG in transforming growth factor β-initiated prostate cancer epithelial-mesenchymal transition. Mol Cell Biol (2011) 1.34
Promoter methylation of the Wnt/beta-catenin signaling antagonist Dkk-3 is associated with poor survival in gastric cancer. Cancer (2009) 1.32
CMTM3, located at the critical tumor suppressor locus 16q22.1, is silenced by CpG methylation in carcinomas and inhibits tumor cell growth through inducing apoptosis. Cancer Res (2009) 1.27
Rare germline mutations in PALB2 and breast cancer risk: a population-based study. Hum Mutat (2012) 1.26
Characterization of the 3a protein of SARS-associated coronavirus in infected vero E6 cells and SARS patients. J Mol Biol (2004) 1.26
KRAB zinc finger protein ZNF382 is a proapoptotic tumor suppressor that represses multiple oncogenes and is commonly silenced in multiple carcinomas. Cancer Res (2010) 1.26
Epigenetic identification of ubiquitin carboxyl-terminal hydrolase L1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors. Hepatology (2008) 1.25
miR-101 is down-regulated by the hepatitis B virus x protein and induces aberrant DNA methylation by targeting DNA methyltransferase 3A. Cell Signal (2012) 1.23
Sphingosine 1-phosphate, present in serum-derived lipoproteins, activates matriptase. J Biol Chem (2002) 1.21
Frequent hypermethylation of RASSF1A and TSLC1, and high viral load of Epstein-Barr Virus DNA in nasopharyngeal carcinoma and matched tumor-adjacent tissues. Neoplasia (2005) 1.19
The tumor suppressor Wnt inhibitory factor 1 is frequently methylated in nasopharyngeal and esophageal carcinomas. Lab Invest (2007) 1.19
Cationic amino acid transporter-2 regulates immunity by modulating arginase activity. PLoS Pathog (2008) 1.19
Epoetin alfa once every 2 weeks is effective for initiation of treatment of anemia of chronic kidney disease. Clin J Am Soc Nephrol (2007) 1.19
Double restriction-enzyme digestion improves the coverage and accuracy of genome-wide CpG methylation profiling by reduced representation bisulfite sequencing. BMC Genomics (2013) 1.18
Epigenetic inactivation of BCL6B, a novel functional tumour suppressor for gastric cancer, is associated with poor survival. Gut (2011) 1.17
STAT3 activation induced by Epstein-Barr virus latent membrane protein1 causes vascular endothelial growth factor expression and cellular invasiveness via JAK3 And ERK signaling. Eur J Cancer (2010) 1.16
LPA receptor heterodimerizes with CD97 to amplify LPA-initiated RHO-dependent signaling and invasion in prostate cancer cells. Cancer Res (2011) 1.15
Purification from human milk of matriptase complexes with secreted serpins: mechanism for inhibition of matriptase other than HAI-1. Am J Physiol Cell Physiol (2008) 1.15
Nurse case management of hypercholesterolemia in patients with coronary heart disease: results of a randomized clinical trial. Am Heart J (2002) 1.15
Paired box gene 5 is a novel tumor suppressor in hepatocellular carcinoma through interaction with p53 signaling pathway. Hepatology (2011) 1.15
CD97, an adhesion receptor on inflammatory cells, stimulates angiogenesis through binding integrin counterreceptors on endothelial cells. Blood (2004) 1.13
The tumor suppressor UCHL1 forms a complex with p53/MDM2/ARF to promote p53 signaling and is frequently silenced in nasopharyngeal carcinoma. Clin Cancer Res (2010) 1.13
Deregulated activation of matriptase in breast cancer cells. Clin Exp Metastasis (2002) 1.12
WNT5A antagonizes WNT/β-catenin signaling and is frequently silenced by promoter CpG methylation in esophageal squamous cell carcinoma. Cancer Biol Ther (2010) 1.12
Hypoxia-driven proliferation of embryonic neural stem/progenitor cells--role of hypoxia-inducible transcription factor-1alpha. FEBS J (2008) 1.11
CDK5 is essential for TGF-β1-induced epithelial-mesenchymal transition and breast cancer progression. Sci Rep (2013) 1.11
Noninvasive imaging of the functional effects of anti-VEGF therapy on tumor cell extravasation and regional blood volume in an experimental brain metastasis model. Clin Exp Metastasis (2009) 1.10
Characterizing the contribution of stem/progenitor cells to tumorigenesis in the Pten-/-TP53-/- prostate cancer model. Stem Cells (2010) 1.10
DACT1, an antagonist to Wnt/β-catenin signaling, suppresses tumor cell growth and is frequently silenced in breast cancer. Breast Cancer Res (2013) 1.10
Computer-navigated iliosacral screw insertion reduces malposition rate and radiation exposure. Clin Orthop Relat Res (2008) 1.10
Authentication of nasopharyngeal carcinoma tumor lines. Int J Cancer (2008) 1.08
Epigenetic repression of miR-132 expression by the hepatitis B virus x protein in hepatitis B virus-related hepatocellular carcinoma. Cell Signal (2013) 1.08
Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition. Am J Pathol (2011) 1.08
A functional polymorphism in the DNA methyltransferase-3A promoter modifies the susceptibility in gastric cancer but not in esophageal carcinoma. BMC Med (2010) 1.08
A survey of methylated candidate tumor suppressor genes in nasopharyngeal carcinoma. Int J Cancer (2011) 1.08
Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies. Br J Haematol (2007) 1.07
One-step nucleic acid amplification assay also predicts axillary lymph node status in breast cancer patients: further molecular diagnostic evidence. Eur J Cancer (2013) 1.06
The epigenetic modifier PRDM5 functions as a tumor suppressor through modulating WNT/β-catenin signaling and is frequently silenced in multiple tumors. PLoS One (2011) 1.05
Hormonal receptors expression in epithelial cells of mammary phyllodes tumors correlates with pathologic grade of the tumor: a multicenter study of 143 cases. Am J Clin Pathol (2002) 1.05
Attenuation of TNFSF10/TRAIL-induced apoptosis by an autophagic survival pathway involving TRAF2- and RIPK1/RIP1-mediated MAPK8/JNK activation. Autophagy (2012) 1.04
Automatic breast cancer grading of histopathological images. Conf Proc IEEE Eng Med Biol Soc (2008) 1.04
Aberrant promoter methylation of DLEC1, a critical 3p22 tumor suppressor for renal cell carcinoma, is associated with more advanced tumor stage. J Urol (2010) 1.04
Small interfering RNAs induce macrophage migration inhibitory factor production and proliferation in breast cancer cells via a double-stranded RNA-dependent protein kinase-dependent mechanism. J Immunol (2008) 1.04
WNT5A is epigenetically silenced in hematologic malignancies and inhibits leukemia cell growth as a tumor suppressor. Blood (2007) 1.04
Genome-wide expression analysis using microarray identified complex signaling pathways modulated by hypoxia in nasopharyngeal carcinoma. Cancer Lett (2007) 1.03
TDAG51 is an ERK signaling target that opposes ERK-mediated HME16C mammary epithelial cell transformation. BMC Cancer (2008) 1.03
TMPRSS2- driven ERG expression in vivo increases self-renewal and maintains expression in a castration resistant subpopulation. PLoS One (2012) 1.03
Spindle cell lesions of the breast--the pathologic differential diagnosis. Breast Cancer Res Treat (2007) 1.03
Relative impact of incorporating pharmacokinetics on predicting in vivo hazard and mode of action from high-throughput in vitro toxicity assays. Toxicol Sci (2013) 1.03
Aberrant methylation of the 8p22 tumor suppressor gene DLC1 in renal cell carcinoma. Cancer Lett (2006) 1.03
STAT3 activation contributes directly to Epstein-Barr virus-mediated invasiveness of nasopharyngeal cancer cells in vitro. Int J Cancer (2009) 1.02
Nuclear accumulation of epidermal growth factor receptor and acceleration of G1/S stage by Epstein-Barr-encoded oncoprotein latent membrane protein 1. Exp Cell Res (2004) 1.01
Cediranib/AZD2171 inhibits bone and brain metastasis in a preclinical model of advanced prostate cancer. Cancer Res (2010) 1.01
Comparative study in the expression of p53, EGFR, TGF-alpha, and cyclin D1 in verrucous carcinoma, verrucous hyperplasia, and squamous cell carcinoma of head and neck region. Appl Immunohistochem Mol Morphol (2002) 1.01
Computer navigation in balloon kyphoplasty reduces the intraoperative radiation exposure. Spine (Phila Pa 1976) (2009) 1.01
Epigenetic silencing of the WNT antagonist Dickkopf 3 disrupts normal Wnt/β-catenin signalling and apoptosis regulation in breast cancer cells. J Cell Mol Med (2013) 1.00